Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446855 · ClinicalTrials.gov registry record · Phase 1
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07446855 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants.
The verdict
NCT07446855, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Interventions
- DRUG Saruparib
- DRUG AZD4956
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2030-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07446855
The ClinicalTrials.gov registry entry for NCT07446855 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saruparib is the first listed.
NCT07446855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07446855 about?
NCT07446855 is a clinical study titled "Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours". The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/m...
What is the current status of trial NCT07446855?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03-17. Estimated completion is 2030-03-29.
What interventions are being tested in trial NCT07446855?
The interventions under investigation include: Saruparib (DRUG), AZD4956 (DRUG).
Who is sponsoring clinical trial NCT07446855?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.